# Safety and Efficacy of Biphasic Human Insulin Compared to EX1000 in Type 2 Diabetes

> **NCT00698802** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 397 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** EX1000
- **DRUG:** biphasic human insulin

## Key facts

- **NCT ID:** NCT00698802
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 397 (ACTUAL)
- **Last updated:** 2015-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00698802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00698802, "Safety and Efficacy of Biphasic Human Insulin Compared to EX1000 in Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00698802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*